ALK gains Torii as Japanese partner for selected immunotherapies
This article was originally published in Scrip
Executive Summary
Japan Tobacco's pharma marketing arm Torii Pharmaceutical will pay €30 million upfront for exclusive Japanese development, commercialisation and distribution rights to immunotherapy products for house dust mite-related asthma and allergic rhinitis developed by ALK-Abell�.